ABL EUROPE SAS – STRASBOURG, FRANCE

ABL Europe SAS – Viral Vector GMP Manufacturing

Europe GMP manufacturing operations

4 Rue Laurent Fries
67400 Illkirch-Graffenstaden
FRANCE

Phone: +33 3 88 55 10 00
E-Mail Us

For directions and a map of our Strasbourg facility, click here.

ABL Europe SAS is a pure-play GMP CMO, completely dedicated to the provision of viral vector GMP contract manufacturing services and a subsidiary of ABL Inc. under the corporate (private) ownership of Institut Mérieux. Formed by the acquisition of Transgene’s GMP manufacturing facilities, ABL has a particularly strong technical & regulatory track record in process development, scale-up & GMP manufacturing of oncolytic and immunotherapeutic viral vectors.

With drug substance, drug product & comprehensive QC testing capabilities in-house, ABL supports biotech and pharma companies in all phases of clinical development and is currently supporting different clients with process validation and GMP supply of oncolytic viral vectors for phase 3 / pivotal efficacy studies being performed globally. Hence, ABL has first-hand experience and understands the regulatory expectations for expanding the chemistry, manufacturing and controls (CMC) content for viral vector therapies used in all stages of clinical development and late stage pivotal studies.

With the recent addition of a brand new 200 L stirred single use bioreactor (SUB) facility and options to readily add 500 L SUB capacity, ABL has strengthened its position in the GMP viral vector CMO market to support clients with a long term manufacturing strategy able to meet their clinical development & product registration objectives.

ABL Europe offers the following manufacturing capacity to its clients, with aseptic production of drug substance and drug product, according to EU & US GMP regulations:

Roller Bottles              < 17 m2

Cell Stacks                   < 60 m2

Stirred SUB                  200 L and 500 L

Fill Finish                     10,000 liquid fill vials per batch

QC release, stability testing, analytical methods qualification and validation, for generic and a wide range of viral vector product specific assays, can be performed in-house by ABL.

ABL EUROPE’S GMP MANUFACTURING FACILITY FOR VIRAL VECTOR PRODUCTION: SARTORIUS STEDIM

A new production facility for the GMP manufacture of viral vectors from non-adherent cell cultures is opening in Strasbourg, France.

read more +

ABL EUROPE’S GMP MANUFACTURING FACILITY FOR VIRAL VECTOR PRODUCTION

A new production facility for the GMP manufacture of viral vectors from non-adherent cell cultures is opening in Strasbourg, France.

read more +